Structure of AZD4573, a potent and selective inhibitor of CDK9

short engagement, selective CDK9 kinase inh.

IV treatment in Ph. I for RR-heme cancers

shortened t1/2 from prior preclin. candidate

J. Med. Chem., Dec. 11, 2020

AstraZeneca, Cambridge, UK / Boston, MA

AstraZeneca selective CDK9 kinase inhibitor

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.